Thailand Medical Cannabis Export in 2025: What Is Actually Realistic?

Since Thailand decriminalized cannabis in 2022, global headlines have swung between "Asia's cannabis hub" and "regulatory chaos." In 2025, the truth sits somewhere in the middle, especially when looking specifically at medical cannabis and export to regulated markets like the EU and UK.

If you are an EU buyer, distributor, or pharmaceutical group evaluating Thailand as a sourcing country, it is critical to separate marketing noise from what is legally and operationally realistic. This is a grounded overview based on current Thai law and what is actually happening on the ground, not what is being pitched at conferences.

1. Legal Snapshot: Where Thailand Really Stands in 2025

Cannabis was decriminalized in June 2022, but only medical use was intended to be legal; extracts over 0.2% THC remain controlled as narcotics. In June 2025, the Ministry of Public Health issued its Notification on Controlled Herbs (Cannabis), reclassifying cannabis flower as a controlled herb under traditional medicine law and restricting sales to licensed dispensaries serving patients with valid medical prescriptions.

An important note: a comprehensive Cannabis and Hemp Act that would create a unified licensing authority and enforcement framework had not passed parliament as of mid-2026. The 2025 controls operate through ministerial notification under existing legislation. For export purposes: tourists and ordinary companies cannot legally export cannabis products. Specially licensed medical operators can, on paper, apply for and hold export licenses for medical cannabis, with heavy oversight, and only to countries where medical cannabis import is clearly legal.

2. Distinguishing Hemp vs High-THC Medical Cannabis

Hemp and Low-THC Products

Thailand has a formal licensing framework for hemp (Cannabis sativa with low THC) covering production, import, export, distribution, and possession, in place since early 2021. For EU buyers, low-THC hemp biomass or derivatives can be structurally easier to work with, but you still need to align with EU novel food rules, cosmetics regulations, and each Member State's position on CBD products before importing.

High-THC Medical Cannabis

High-THC inflorescence and extracts fall under narcotics control and controlled-herb rules. Export is legally possible only as medical cannabis, to pharmaceutical or medical systems abroad, subject to Thai FDA and Ministry of Public Health licensing, alignment with the destination country's narcotics import laws, and documented medical use. In practice this pathway is narrow, bureaucratic, and heavily scrutinized at every stage.

3. EU Reality: What It Takes to Import From Thailand

From the EU side, "Thailand has legal cannabis" is completely irrelevant to your compliance analysis. What matters is whether a Thai supply chain can meet European pharmaceutical standards. For EU or UK import of medical cannabis, regulators and buyers typically expect:

• GACP-compliant cultivation for the flower.
• EU-GMP manufacturing for the final dosage form or bulk product entering the medical supply chain.
• A licensed EU importer or wholesaler with narcotics permits in the destination country.
• Full documentation: batch certificates of analysis from ISO/IEC 17025-accredited laboratories, stability data, validated methods, and traceability back to the cultivation site.

4. Market Reality: How Many Thai Groups Are Truly Export-Ready?

As of late 2025, industry reports citing DTAM data indicated approximately 149 out of over 11,800 legacy-licensed operators held DTAM GACP certification. That figure had grown to 217 by February 2026, per DTAM. Either way, it represents the domestic minimum, not EU export readiness. Very few Thai sites have obtained internationally recognized GACP certification, and those with full EU-GMP for finished products are rarer still. New Thai regulations in 2025 push domestic operators toward pharmaceutical-grade compliance or exit, which is positive for serious medical supply but disruptive for the majority of the existing operator base. You can find strong assets and serious teams in Thailand. They are the exception, not the rule.

5. What Is Realistic in 2025

Treat Thailand as a medium-term sourcing option, not an immediate volume solution. Regulatory tightening and high quality expectations mean that 2025 is more about pilot projects, audits, and supplier qualification than about filling large country tenders from Thai product.

Consider the GACP biomass plus EU-based finishing model. A practical structure for many buyers involves GACP-compliant cultivation in Thailand, export of biomass under narcotics and health-product licenses, and final processing, release, and QP certification under EU-GMP in Europe. This respects both Thai law and EU expectations and reduces pressure on Thai sites to immediately hold full EU-GMP for finished product.

Plan for heavy due diligence and long lead times. A serious Thailand-to-EU supply chain is typically a 12 to 24 month project. Plan for on-site audits, multiple pilot batches to confirm potency and contamination control, and time to align Thai documentation with EU importer templates and regulator expectations.

6. How Buyers Should Approach Thailand in 2025

Start with law, not hype. Map what is actually legal on the Thai side and in your home market for each product type you are considering: flower, oil, finished product, API, hemp derivatives.

Shortlist only operators with real compliance evidence. Ask for valid Thai cultivation and narcotics or hemp licenses, GACP documentation and third-party audit reports (not just claims to follow GACP), laboratory accreditation details, example certificates of analysis, and clear ownership and corporate structure.

Audit logistics and export capability. A strong cultivation facility is not enough. You need a clear export licensing pathway, validated packaging and temperature-control systems, and a clean history with Thai regulators.

Build a staged plan. Rather than "we will buy X kg per month from Thailand," a better strategy is: Stage 1, legal and regulatory feasibility mapping; Stage 2, facility audits and pilot batches; Stage 3, documentation and stability program; Stage 4, first small commercial shipments if all previous stages succeed.

Final Thoughts

Thailand has real fundamentals for medical cannabis: climate and agricultural expertise, a domestic medical market under tighter supervision, and serious GACP-oriented groups working to integrate into EU-GMP supply chains. But "Thailand as your next EU medical cannabis supply source" is not a plug-and-play proposition in 2025. It is a regulated, slow-moving project that only makes sense if you treat it like any other pharmaceutical supply chain: documentation first, quality first, logistics first. DeeMED Consulting operates exactly at this intersection, between Thai regulation, on-the-ground operations, and overseas buyer expectations.

This article was originally published on LinkedIn on December 2, 2025. Read the original post ↗